Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome.
about
Potential Impact of Integrating HIV Surveillance and Clinic Data on Retention-in-Care Estimates and Re-Engagement EffortsAfrican American race and HIV virological suppression: beyond disparities in clinic attendance.Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa.Adherence to HAART among patients with HIV: breakthroughs and barriers.Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users.How well do clinicians estimate patients' adherence to combination antiretroviral therapy?Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics.The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with menCost-effectiveness of HIV screening in patients older than 55 years of age.Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure.Predictors of antiretroviral treatment failure in an urban HIV clinic.R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.Racial disparities in HIV virologic failure: do missed visits matter?The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans.Neighborhood Characteristics Associated with Achievement and Maintenance of HIV Viral Suppression Among Persons Newly Diagnosed with HIV in New York City.The physical, emotional and interpersonal impact of HAART: exploring the realities of HIV seropositive individuals on combination therapy.Randomized controlled trial to evaluate the impact of pharmaceutical care on therapeutic success in HIV-infected patients in Southern Brazil.Viral load in tissues during the early and chronic phase of non-pathogenic SIVagm infection.Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence.Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients.
P2860
Q31128135-BD7BCE19-B7CE-47C3-B9C9-B544F2C2A4E6Q33735032-D4A28172-03F7-425F-9F62-A62840AE92BEQ33988155-0B40AC2E-B33A-44F2-9F5A-3AF615AEA0EFQ34451025-FA5EAF36-CE88-4597-B2D5-360443E35E54Q34664263-D4AF156D-6B24-44B3-8449-26633DE85CF2Q34741365-1FAAEE8C-F9FD-40B0-929F-C36574CA91E6Q34742740-2C6516AB-D254-41D1-87A1-B3121C385F0CQ35197301-9C8C352E-888B-4A26-B913-F1925EE09137Q35624701-F9B2DFD1-6CCD-4C7E-A67A-AEF32413D127Q36191220-29826B4E-B007-447D-8448-BD6A6DD9A181Q36203458-980F48FC-FA7B-439C-8DC1-2FE828B3FA27Q36628011-C42686FB-3712-4030-965F-63C629B96995Q36880577-18087073-F8A3-4023-AAB1-553E7B39E397Q37397905-77511100-4B85-469C-80F1-686D6509D006Q37610678-B278A2F9-0E76-4107-BC7F-604F252F8B71Q38979755-698D9971-509A-4A43-ACBE-C37A633A34E1Q40427185-CD5D34A0-5D52-4E47-9F0E-A7A0D36830E3Q42274383-52DB76E1-28C8-4640-8471-EB2F6C7D3978Q43702789-83004BB8-CF58-4910-B7E7-E522E9D1550AQ46472600-5E8AFFAA-8528-453A-B471-C8118D2B4B23Q52106605-7CAFDA10-D42D-4AD5-8A7E-3A9EA0EDF9D9
P2860
Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Human immunodeficiency virus 1 ...... ictors of virological outcome.
@en
Human immunodeficiency virus 1 ...... ictors of virological outcome.
@nl
type
label
Human immunodeficiency virus 1 ...... ictors of virological outcome.
@en
Human immunodeficiency virus 1 ...... ictors of virological outcome.
@nl
prefLabel
Human immunodeficiency virus 1 ...... ictors of virological outcome.
@en
Human immunodeficiency virus 1 ...... ictors of virological outcome.
@nl
P2093
P1476
Human immunodeficiency virus 1 ...... ictors of virological outcome.
@en
P2093
Gripshover BM
Lederman MM
P304
P356
10.1001/ARCHINTE.159.15.1771
P407
P577
1999-08-01T00:00:00Z